<DOC>
	<DOCNO>NCT02109172</DOCNO>
	<brief_summary>This study evaluate safety efficacy twice daily TD-4208 placebo administer use jet nebulizer 7 day cross-over design patient moderate severe chronic obstructive pulmonary disease .</brief_summary>
	<brief_title>A 7-Day Cross-over Study QD ( Once Daily ) BID ( Twice Daily ) TD-4208 Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Subject must negative pregnancy test , must prepare use effective contraception childbearing potential Subject capable perform reproducible spirometry maneuver Subject postbronchodilator FEV1/FVC ( forced expiratory volume 1 second/forced vital capacity ) ratio &lt; 0.7 Subject moderatetosevere stable COPD ( Stage 2 3 accord Global Initiative Treatment Obstructive Lung Disease ( GOLD ) Guidelines ) Subject postbronchodilator FEV1 great equal 30 % le 80 % predict normal Subject demonstrate postipratropium FEV1 response ≥ 12 % ≥ 200 mL preipratropium FEV1 response Subject current past smoking history least 10 packyears . Subject significant respiratory disease disorder COPD would affect interpretation data study Subject history reaction hypersensitivity inhale anticholinergic betaagonist agent Subject suffers medical condition would preclude use inhaled anticholinergic agent Subject hospitalize COPD pneumonia within 12 week . Subject require longterm oxygen therapy ( &gt; 15 hour day )</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>COPD</keyword>
</DOC>